Wang Xiaoyan, Ding Jiaqi, Chen Lijia, Wang Hongtian, Wang Xueyan
Department of Allergy,Beijing Shijitan Hospital,Capital Medical University,Beijing,100038,China.
Department of Otolaryngology,Beijing Shijitan Hospital Affiliated to Che Medical University.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024 Mar;38(3):195-199. doi: 10.13201/j.issn.2096-7993.2024.03.003.
To explore the allergen components of birch pollen in the Beijing area and interpret its clinical significance. A total of 58 patients with birch pollen allergy were included in the cross-sectional study and divided into allergic rhinitis(AR) and allergic asthma(AA) groups according to clinical manifestations. Concentration of birch pollen allergen sIgE, as well as Bet v 1, Bet v 2, Bet v 4 and Bet v 6 sIgE were detected by ImmunoCAP immunolinked immunoassay. Differences of sIgE concentration of birch pollen allergen component in AR and AA were analyzed. There were 44(75.9%) cases of AR and 14(24.1%) cases of AA were enrolled. All the 18 patients with spring pollen allergy were AR patients without AA. There were 40 cases with both spring and autumn pollen allergy, of which 26 cases(65%) were AR and 14 cases(35%) were AA. The sIgE of birch pollen allergen was level 2 or above in all subjects. 94.8% were positive for any four allergen components. 77.6% were mono-sensitized to any allergen component while 17.2% were dual-sensitized. The positive rate of Bet v 1 and/or Bet v 2 was 93.1%. The positive rates of four protein components were: Bet v 1(82.8%), Bet v 2(29.3%), Bet v 6(1.7%), Bet v 4(0%). sIgE of birch pollen was positively correlated with sIgE level of Betv 1(=0.898, <0.001). The sIgE concentration of Bet v2 in AA group was significantly higher than that in AR group([4.34±14.35] kUA/L vs [1.56±3.26] kUA/L, <0.05). There was no significant difference in other components. Bet v 1 is the main allergen component of birch pollen in the Beijing area, and Bet v 1 plus Bet v 2 can diagnose more than 90% of birch pollen allergy.
探索北京地区桦树花粉的过敏原成分并阐释其临床意义。本横断面研究共纳入58例桦树花粉过敏患者,根据临床表现分为变应性鼻炎(AR)组和变应性哮喘(AA)组。采用免疫捕获免疫分析检测桦树花粉过敏原sIgE以及Bet v 1、Bet v 2、Bet v 4和Bet v 6的sIgE浓度。分析AR组和AA组中桦树花粉过敏原成分sIgE浓度的差异。共纳入44例(75.9%)AR患者和14例(24.1%)AA患者。18例春季花粉过敏患者均为AR患者,无AA患者。40例春、秋季花粉过敏患者中,26例(65%)为AR患者,14例(35%)为AA患者。所有受试者的桦树花粉过敏原sIgE均为2级及以上。94.8%的患者对任意四种过敏原成分呈阳性。77.6%的患者对任意一种过敏原成分单致敏,17.2%的患者双致敏。Bet v 1和/或Bet v 2的阳性率为93.1%。四种蛋白质成分的阳性率分别为:Bet v 1(82.8%)、Bet v 2(29.3%)、Bet v 6(1.7%)、Bet v 4(0%)。桦树花粉sIgE与Betv 1的sIgE水平呈正相关(=0.898,<0.001)。AA组中Bet v2的sIgE浓度显著高于AR组([4.34±14.35] kUA/L比[1.56±3.26] kUA/L,<0.05)。其他成分无显著差异。Bet v 1是北京地区桦树花粉的主要过敏原成分,Bet v 1加Bet v 2可诊断90%以上的桦树花粉过敏。